Does LL-37 Help Antimicrobial Research? (Mechanisms Explained)
Research published in Nature Reviews Microbiology identified LL-37 as the most extensively studied antimicrobial peptide in human immunology. Not because it's the most potent bacterial killer, but because it's the only cathelicidin encoded in the human genome. That singularity makes LL-37 irreplaceable as a translational research tool: every mechanism discovered, every resistance pathway mapped, every structural modification tested provides direct insight into how human innate immunity functions at the molecular level. Most antimicrobial peptides studied in labs come from amphibians, insects, or synthetic libraries. LL-37 is the rare exception where findings translate immediately to human clinical relevance.
We've worked with research teams across multiple institutions investigating antimicrobial peptide mechanisms. The pattern is consistent: LL-37 appears in nearly every high-impact study on host defense peptides, membrane disruption kinetics, and immune modulation because it represents the human baseline against which all other candidates are measured.
Does LL-37 help antimicrobial research?
Yes. LL-37 help antimicrobial research by serving as the primary translational model for human cathelicidin function, bacterial membrane interaction studies, and therapeutic peptide design. As the sole human cathelicidin, LL-37 provides researchers with mechanistic insight into how the body's innate immune system kills pathogens, modulates inflammation, and responds to resistant bacteria. Studies using LL-37 have identified at least four distinct mechanisms of antimicrobial action and contributed to the development of over 30 synthetic analogs currently in preclinical or clinical investigation.
The assumption that LL-37 help antimicrobial research solely through its bacterial killing capacity misses the bigger picture. Its real value lies in what it reveals about immune system architecture and adaptive responses. LL-37 doesn't just punch holes in bacterial membranes; it recruits immune cells, neutralizes endotoxins, modulates cytokine release, and influences biofilm formation in ways that change how researchers approach infection control. This article covers exactly how LL-37 functions across multiple research domains, what makes it structurally unique among antimicrobial peptides, and which specific research applications depend on its use.
Why LL-37 Serves as the Gold Standard Translational Model
LL-37 help antimicrobial research primarily because it eliminates the translational gap that plagues most antimicrobial peptide studies. When researchers identify a promising antimicrobial peptide from frog skin or insect hemolymph, they face an immediate question: will this mechanism function identically in human physiology? LL-37 bypasses that uncertainty entirely. It is human physiology. The peptide is cleaved from the C-terminal end of the human cationic antimicrobial protein hCAP18 by proteinase 3, primarily in neutrophils but also in epithelial cells lining the respiratory tract, gastrointestinal system, and skin. This endogenous production pathway means every mechanistic insight derived from LL-37 studies applies directly to how the human body fights infection without requiring cross-species validation.
The structural features that make LL-37 antimicrobially active. An alpha-helical conformation, net positive charge (+6 at physiological pH), and amphipathic orientation. Are shared across cathelicidins in other mammals, but the exact amino acid sequence is human-specific. Research published in the Journal of Biological Chemistry demonstrated that even single amino acid substitutions in the LL-37 sequence alter antimicrobial potency by 40–70%, meaning subtle structural variations matter enormously. Studies using LL-37 therefore reveal not just general principles of antimicrobial peptide function but specific structure-activity relationships applicable to human therapeutic development. Synthetic analogs designed to improve stability, reduce cytotoxicity, or enhance bacterial selectivity all begin with the LL-37 backbone as the reference point.
Beyond direct bacterial killing, LL-37 help antimicrobial research by modeling immunomodulatory functions that most traditional antibiotics lack entirely. The peptide binds to bacterial lipopolysaccharide (LPS) and lipoteichoic acid (LTA), neutralizing their pro-inflammatory effects and reducing septic shock risk in animal models. It also acts as a chemoattractant for neutrophils, monocytes, and T cells by binding to the formyl peptide receptor-like 1 (FPRL1), effectively recruiting additional immune firepower to sites of infection. These dual roles. Direct antimicrobial action plus immune system coordination. Make LL-37 a uniquely valuable research model for understanding how the body integrates chemical killing with cellular immunity. Researchers studying next-generation antimicrobials increasingly prioritize this dual functionality, and LL-37 provides the template.
In our experience supporting research labs with high-purity peptide synthesis, LL-37 consistently ranks among the top five requested compounds across immunology, microbiology, and pharmacology research programs. The reason isn't novelty. It's necessity. Any research question about how human antimicrobial peptides interact with bacterial membranes, modulate inflammation, or resist proteolytic degradation starts with LL-37 as the benchmark. The peptide's extensive citation history, well-characterized mechanism, and direct clinical relevance create a network effect: the more LL-37 is studied, the more valuable each new study becomes because it builds on a shared reference framework that researchers worldwide recognize and trust.
How LL-37 Reveals Membrane Disruption Mechanisms
Most antibiotics target specific bacterial enzymes or metabolic pathways. Beta-lactams inhibit cell wall synthesis, fluoroquinolones block DNA gyrase, aminoglycosides disrupt protein synthesis. LL-37 help antimicrobial research by demonstrating a fundamentally different killing mechanism: direct physical disruption of bacterial membrane integrity through electrostatic interaction and insertion. The peptide's cationic charge (+6) attracts it to the anionic phospholipid head groups found predominantly in bacterial membranes (phosphatidylglycerol, cardiolipin), while mammalian cell membranes. Rich in zwitterionic phosphatidylcholine and cholesterol. Resist binding. This charge-based selectivity is the foundational principle behind nearly every antimicrobial peptide in development, and LL-37 studies provided the first high-resolution mechanistic data demonstrating how it works in a human-derived peptide.
Once bound to the bacterial membrane, LL-37 adopts an amphipathic alpha-helical structure with hydrophobic residues oriented toward the lipid bilayer and hydrophilic residues facing outward. Research using fluorescence microscopy and atomic force microscopy published in the Proceedings of the National Academy of Sciences showed that LL-37 doesn't simply poke random holes. It forms structured pores through either the barrel-stave model (peptides align perpendicular to the membrane) or the carpet model (peptides coat the surface and cause micellization). Which model dominates depends on peptide concentration, bacterial membrane composition, and ionic strength of the surrounding environment. Studies manipulating these variables with LL-37 as the test peptide have generated the core dataset that informs how researchers predict pore-forming behavior in novel antimicrobial peptides.
The kinetics of membrane disruption matter as much as the mechanism itself. LL-37 achieves bacterial killing within minutes at concentrations as low as 2–8 μg/mL against Gram-positive organisms like Staphylococcus aureus and 8–32 μg/mL against Gram-negative bacteria such as Escherichia coli and Pseudomonas aeruginosa. These minimum inhibitory concentration (MIC) values, established through thousands of replicated assays, serve as the reference standard against which new antimicrobial peptides are benchmarked. If a synthetic analog shows MIC values significantly higher than LL-37 against the same bacterial strain under identical conditions, it's considered less promising for therapeutic development. Regardless of other favorable properties.
Crucially, LL-37 help antimicrobial research by revealing how bacteria develop resistance to membrane-disrupting peptides, a question with profound implications for therapeutic design. Unlike resistance to conventional antibiotics. Which typically arises through point mutations in target enzymes or acquisition of resistance genes. Resistance to LL-37 emerges through membrane remodeling. Bacteria modify lipid composition (increasing positively charged lysyl-phosphatidylglycerol to repel cationic peptides), produce proteases that degrade LL-37, or express efflux pumps that expel the peptide before membrane insertion occurs. Research groups studying these adaptive mechanisms rely on LL-37 as the challenge compound because its structure and activity are so thoroughly characterized that any change in bacterial response can be attributed specifically to the resistance mechanism under investigation rather than variability in the peptide itself.
LL-37's Role in Immune Modulation Research
The direct bacterial killing capacity of LL-37 represents only half its research utility. LL-37 help antimicrobial research equally through its immunomodulatory functions, which bridge innate and adaptive immunity in ways that challenge the traditional separation between antimicrobial agents and immune signaling molecules. This dual functionality has redirected significant research effort toward understanding how antimicrobial peptides don't just kill pathogens but actively shape the immune response to infection. A paradigm shift from viewing them as simple chemical disinfectants to recognizing them as immune system coordinators.
LL-37 acts as a chemotactic agent by binding to formyl peptide receptor-like 1 (FPRL1) on neutrophils, monocytes, and mast cells, triggering directed migration toward sites of infection. Studies published in the Journal of Immunology demonstrated that LL-37 at concentrations as low as 0.1–1 μg/mL. Well below bactericidal thresholds. Induces chemotaxis with potency comparable to classical chemoattractants like fMLP and IL-8. This finding fundamentally changed how researchers think about antimicrobial peptide dosing: sublethal concentrations that don't kill bacteria directly can still contribute to infection clearance by recruiting professional phagocytes to the site. Research into therapeutic applications now investigates whether LL-37 analogs can be dosed specifically for immune recruitment rather than direct killing, potentially reducing cytotoxicity concerns while maintaining efficacy.
Another critical immunomodulatory function: LL-37 neutralizes bacterial endotoxins. Lipopolysaccharide (LPS) from Gram-negative bacteria and lipoteichoic acid (LTA) from Gram-positive bacteria trigger excessive pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6) that can lead to septic shock. LL-37 binds directly to LPS and LTA, preventing their interaction with Toll-like receptors (TLR4 and TLR2 respectively) and dampening the inflammatory cascade. Animal studies using LL-37 pretreatment showed 60–75% reductions in TNF-α levels following LPS challenge compared to controls. This endotoxin-neutralizing capacity is now a standard screening criterion for antimicrobial peptides in development. Candidates that kill bacteria but fail to neutralize endotoxins are considered less therapeutically promising because they address only half the infection pathology.
LL-37 also influences adaptive immunity through dendritic cell maturation and T cell differentiation. The peptide upregulates co-stimulatory molecules (CD80, CD86) on dendritic cells, enhancing their antigen-presentation capacity and shifting T cell responses toward Th1 polarization. Critical for intracellular pathogen clearance. Research programs investigating vaccine adjuvants have incorporated LL-37 or synthetic analogs specifically to leverage this immunostimulatory effect. The mechanistic data generated from these studies. Optimal concentrations, timing of administration, synergy with conventional adjuvants. All derive from foundational LL-37 research establishing the peptide's immune-activating properties.
LL-37 Help Antimicrobial Research: Mechanism Comparison
LL-37's multifunctional properties across different research applications are best understood through direct comparison. The following table maps how LL-37 contributes to distinct areas of antimicrobial investigation.
| Research Application | Mechanism Studied | Typical Concentration Range | Key Finding LL-37 Revealed | Professional Assessment |
|---|---|---|---|---|
| Bacterial membrane disruption | Pore formation via electrostatic binding and insertion | 2–32 μg/mL (MIC range) | Charge-based selectivity for bacterial membranes; barrel-stave and carpet models of pore formation | Gold standard for membrane disruption kinetics. No alternative human peptide offers comparable data depth |
| Resistance mechanism identification | Bacterial membrane remodeling, protease production, efflux pumps | 4–64 μg/mL (adaptive response threshold) | Bacteria increase lysyl-phosphatidylglycerol content to repel cationic peptides | Essential model for understanding how resistance develops without target mutation |
| Immune cell recruitment | FPRL1 receptor binding and chemotaxis | 0.1–1 μg/mL (sublethal) | Sublethal concentrations recruit neutrophils and monocytes as effectively as IL-8 | Redefined antimicrobial peptide dosing strategies to include immune coordination |
| Endotoxin neutralization | LPS/LTA binding and TLR inhibition | 5–20 μg/mL | Direct binding prevents TLR4/TLR2 activation, reducing TNF-α by 60–75% in animal models | Critical data for sepsis research. Informs design of anti-inflammatory antimicrobials |
| Biofilm disruption | Inhibition of initial bacterial adhesion and established biofilm degradation | 10–50 μg/mL | Prevents Pseudomonas aeruginosa biofilm formation at 10 μg/mL; disrupts mature biofilms at 40–50 μg/mL | Foundational reference for biofilm-targeted peptides. Established concentration-response curves |
Key Takeaways
- LL-37 is the only cathelicidin peptide encoded in the human genome, making it irreplaceable as a translational research model for understanding human innate immunity.
- The peptide kills bacteria through membrane disruption at MIC values of 2–8 μg/mL (Gram-positive) and 8–32 μg/mL (Gram-negative), serving as the benchmark for evaluating new antimicrobial peptides.
- LL-37 neutralizes bacterial endotoxins by binding LPS and LTA, reducing pro-inflammatory cytokine release by 60–75% in animal models and informing sepsis treatment research.
- Sublethal concentrations (0.1–1 μg/mL) recruit immune cells through FPRL1 receptor binding, demonstrating that antimicrobial peptides coordinate immunity beyond direct bacterial killing.
- Bacterial resistance to LL-37 develops through membrane remodeling rather than target mutation, providing researchers with a model for studying adaptive resistance mechanisms that differ fundamentally from conventional antibiotic resistance.
- Over 30 synthetic LL-37 analogs are currently in preclinical or clinical development, all derived from mechanistic insights gained through foundational LL-37 research.
What If: LL-37 Antimicrobial Research Scenarios
What If a Bacterial Strain Shows Resistance to LL-37 in Vitro?
Test the strain against structurally modified LL-37 analogs with altered charge distribution or hydrophobicity to identify which specific structural feature the bacteria are resisting. Resistance to LL-37 typically manifests through membrane modification (increased lysyl-phosphatidylglycerol content), protease secretion, or efflux pump upregulation. Each mechanism responds differently to structural variants. If the resistant strain remains susceptible to an analog with reduced net charge but maintained amphipathicity, the resistance mechanism likely involves electrostatic repulsion rather than proteolytic degradation. Mapping resistance patterns across a panel of LL-37 variants generates mechanistic data that informs therapeutic analog design and predicts cross-resistance risk.
What If LL-37 Shows Cytotoxicity Against Mammalian Cells at Bactericidal Concentrations?
Quantify the therapeutic index by determining the minimum hemolytic concentration (MHC) against human red blood cells and comparing it to the MIC against target bacteria. LL-37's therapeutic window is typically 4–10 fold (MHC 32–64 μg/mL vs MIC 2–8 μg/mL for Gram-positive bacteria), but this narrows significantly against Gram-negative organisms. If cytotoxicity appears at or below bactericidal concentrations, researchers typically modify the peptide sequence to increase selectivity. Shortening the peptide, reducing overall hydrophobicity, or incorporating D-amino acids to resist proteolysis without increasing membrane lytic activity. The extensive structure-activity relationship data generated from LL-37 modifications provides a rational design framework for improving selectivity while maintaining antimicrobial potency.
What If Researchers Need to Study Antimicrobial Peptide Activity in Physiological Conditions?
Account for the fact that LL-37 antimicrobial activity decreases 50–90% in the presence of physiological salt concentrations (150 mM NaCl), serum proteins, or glycosaminoglycans compared to standard laboratory buffer conditions. This dramatic reduction occurs because high ionic strength shields electrostatic interactions between the cationic peptide and anionic bacterial membranes, while serum albumin binds LL-37 and reduces free peptide concentration. Studies establishing clinical relevance must test LL-37 activity in media supplemented with 10–50% serum or synthetic wound fluid rather than relying solely on minimal media MIC values. The discrepancy between in vitro potency and physiological activity is a central challenge in antimicrobial peptide drug development, and LL-37 serves as the primary model for understanding this translational gap.
The Evidence-Based Truth About LL-37 in Antimicrobial Research
Here's the honest answer: LL-37 help antimicrobial research not because it's the most potent bacterial killer. It isn't. Dozens of synthetic peptides and natural analogs demonstrate lower MIC values, broader spectrum activity, and better resistance to proteolytic degradation. LL-37's value lies in being the human reference standard. Every mechanistic insight, every structure-activity relationship, every resistance pathway mapped contributes to a shared knowledge base that researchers worldwide use to design better therapeutics. Remove LL-37 from the research pipeline and you lose the translational anchor connecting basic peptide science to human clinical application.
The reality is that LL-37 itself will likely never become a frontline therapeutic. Its susceptibility to proteolytic cleavage, activity reduction in physiological salt concentrations, and modest therapeutic index against Gram-negative bacteria all limit direct clinical use. But that's not the point. The 30+ synthetic analogs currently in development. Incorporating D-amino acids for protease resistance, optimized charge distribution for improved selectivity, and truncated sequences for better tissue penetration. All exist because LL-37 research identified which structural modifications matter and which don't. The peptide's greatest contribution to antimicrobial research is the roadmap it provides for everything that comes after it.
Real Peptides supplies research-grade LL-37 synthesized through small-batch production with exact amino acid sequencing verified through mass spectrometry. The demand from research institutions remains consistently high because LL-37 appears in nearly every high-impact study on antimicrobial peptide mechanisms, immune modulation, and therapeutic development. For labs investigating bacterial resistance, membrane biophysics, or innate immune signaling, LL-37 remains the essential starting point. Not the only tool, but the one that provides the most direct path from laboratory observation to human clinical relevance.
If your research program centers on antimicrobial peptide development, bacterial membrane interactions, or immune system modulation, LL-37 is the benchmark against which all other findings will be measured. The peptide's extensive characterization eliminates variability and allows precise mechanistic questions to be asked and answered. For labs seeking high-purity research peptides across multiple investigational areas, explore our complete peptide collection and discover how precision synthesis supports reproducible, publication-grade research outcomes.
Frequently Asked Questions
How does LL-37 kill bacteria differently than conventional antibiotics?
▼
LL-37 kills bacteria through direct physical disruption of the cell membrane via electrostatic binding and pore formation, rather than targeting specific enzymes or metabolic pathways like conventional antibiotics. The peptide’s cationic charge (+6) attracts it to anionic bacterial membrane lipids, where it inserts and forms pores that cause membrane depolarization and cell lysis within minutes. This mechanism makes resistance development fundamentally different — bacteria must remodel their entire membrane composition rather than mutate a single enzyme target, which is why LL-37 serves as a critical model for understanding non-enzymatic antimicrobial mechanisms.
Can LL-37 be used directly as a therapeutic antimicrobial drug?
▼
LL-37 itself is unlikely to become a frontline therapeutic due to several limitations: susceptibility to proteolytic degradation by bacterial and human proteases, 50–90% activity reduction in physiological salt concentrations and serum, and a narrow therapeutic index (4–10 fold difference between bactericidal and cytotoxic concentrations). However, over 30 synthetic LL-37 analogs incorporating structural modifications — D-amino acids for protease resistance, optimized charge distribution, truncated sequences — are currently in preclinical or clinical development. The primary clinical value of LL-37 research is informing the design of these next-generation peptides rather than direct therapeutic use of the native sequence.
What is the minimum inhibitory concentration of LL-37 against common bacterial pathogens?
▼
LL-37 demonstrates MIC values of 2–8 μg/mL against Gram-positive bacteria like Staphylococcus aureus and 8–32 μg/mL against Gram-negative organisms including Escherichia coli and Pseudomonas aeruginosa under standard laboratory conditions (low ionic strength buffer). These values increase significantly — often by 5–20 fold — in the presence of physiological salt concentrations (150 mM NaCl) or serum proteins, which is why in vitro MIC data must be validated under conditions that mimic the infection site. The MIC range established for LL-37 serves as the reference benchmark for evaluating new antimicrobial peptides.
How do bacteria develop resistance to LL-37?
▼
Bacteria develop resistance to LL-37 through three primary mechanisms: membrane remodeling (increasing positively charged lysyl-phosphatidylglycerol to repel the cationic peptide), secretion of proteases that degrade LL-37 before membrane insertion, and upregulation of efflux pumps that expel the peptide. Unlike conventional antibiotic resistance — which typically arises from point mutations in target enzymes — LL-37 resistance requires coordinated changes in membrane composition or expression of degradative enzymes. This distinction makes LL-37 an essential research model for understanding adaptive resistance mechanisms that don’t involve target mutation and may be more difficult for bacteria to acquire rapidly.
Does LL-37 have functions beyond killing bacteria?
▼
Yes — LL-37 functions as an immune modulator through multiple pathways: it recruits neutrophils and monocytes by binding FPRL1 receptors at sublethal concentrations (0.1–1 μg/mL), neutralizes bacterial endotoxins (LPS and LTA) to prevent excessive inflammation, promotes wound healing by stimulating angiogenesis and keratinocyte migration, and influences adaptive immunity by enhancing dendritic cell maturation. These immunomodulatory functions occur at concentrations below those required for direct bacterial killing and represent a distinct therapeutic mechanism. Research into LL-37’s immune coordination roles has fundamentally changed how antimicrobial peptides are conceptualized — not just as chemical disinfectants but as immune system signaling molecules.
Why is LL-37 used more frequently in research than other antimicrobial peptides?
▼
LL-37 is the only cathelicidin encoded in the human genome, making it uniquely valuable as a translational research model — findings derived from LL-37 studies apply directly to human physiology without requiring cross-species validation. Most antimicrobial peptides studied in labs come from frogs, insects, or synthetic libraries, creating uncertainty about whether mechanisms identified in those peptides function identically in humans. LL-37 eliminates that gap. Additionally, its extensive characterization in published literature creates a network effect: the more LL-37 is studied, the more valuable new studies become because they build on a shared reference framework recognized worldwide.
What concentration of LL-37 is needed to disrupt established bacterial biofilms?
▼
LL-37 prevents initial biofilm formation by Pseudomonas aeruginosa at concentrations as low as 10 μg/mL but requires 40–50 μg/mL to disrupt mature, established biofilms — concentrations 4–6 times higher than planktonic MIC values. This difference reflects the protective barrier created by extracellular polymeric substances in biofilms, which limit peptide penetration and reduce effective concentration at the bacterial cell surface. Research using LL-37 to understand biofilm resistance has established that antimicrobial peptides targeting biofilms must either penetrate the matrix more effectively or be combined with matrix-degrading enzymes to achieve therapeutic concentrations at the site of bacterial attachment.
How does salt concentration affect LL-37 antimicrobial activity?
▼
Physiological salt concentrations (150 mM NaCl) reduce LL-37 antimicrobial activity by 50–90% compared to low-ionic-strength laboratory buffers because high salt shields the electrostatic interactions between the cationic peptide and anionic bacterial membrane lipids. This ionic strength dependence is one of the primary challenges in translating in vitro antimicrobial peptide research to clinical applications, as infection sites — blood, tissue, wound fluid — all contain salt concentrations that dramatically reduce peptide potency. LL-37 research has quantified this effect more thoroughly than any other antimicrobial peptide, establishing the testing standards that now guide evaluation of therapeutic candidates under physiologically relevant conditions.
Can LL-37 research inform development of peptides against antibiotic-resistant bacteria?
▼
Yes — LL-37’s membrane-disruption mechanism bypasses the enzyme targets where most antibiotic resistance mutations occur, making it a valuable model for developing therapeutics against MRSA, VRE, and multidrug-resistant Gram-negative bacteria. Resistance to LL-37 requires bacteria to fundamentally remodel membrane composition or express degradative enzymes — changes that are metabolically costly and less easily transferred via plasmids than single-gene resistance determinants. Research mapping which bacterial species develop LL-37 resistance and through which mechanisms informs the design of synthetic analogs less susceptible to those specific resistance pathways, creating a rational development framework for peptides targeting resistant organisms.
What role does LL-37 play in sepsis research?
▼
LL-37 neutralizes bacterial endotoxins (LPS from Gram-negative bacteria and LTA from Gram-positive bacteria) by binding directly to these molecules and preventing their interaction with Toll-like receptors TLR4 and TLR2, which trigger the pro-inflammatory cytokine cascade leading to septic shock. Animal studies using LL-37 pretreatment showed 60–75% reductions in TNF-α levels following LPS challenge. This endotoxin-neutralizing capacity has redirected sepsis research toward antimicrobial peptides that address both the infection (bacterial killing) and the inflammatory pathology (cytokine storm) simultaneously, rather than treating each component separately with antibiotics plus anti-inflammatory drugs.
How is LL-37 synthesized for research use?
▼
Research-grade LL-37 is synthesized through solid-phase peptide synthesis (SPPS) using Fmoc chemistry, which builds the 37-amino-acid sequence stepwise from the C-terminus to the N-terminus. Each amino acid coupling is verified, and the final peptide is cleaved from the resin, purified using reverse-phase high-performance liquid chromatography (RP-HPLC) to >95% purity, and verified through mass spectrometry to confirm the exact molecular weight (4493.3 Da) and sequence accuracy. High-purity synthesis is critical because even single amino acid substitutions or deletions alter LL-37 antimicrobial activity by 40–70%, making sequence fidelity essential for reproducible research outcomes.
What makes LL-37 structurally unique among antimicrobial peptides?
▼
LL-37 adopts an amphipathic alpha-helical structure upon membrane contact, with hydrophobic residues (leucine, isoleucine, phenylalanine) oriented toward the lipid bilayer and cationic residues (lysine, arginine) facing outward toward the aqueous environment. This amphipathic arrangement is critical for membrane insertion — purely hydrophobic or purely charged peptides lack antimicrobial activity. The specific amino acid sequence of LL-37 creates a net positive charge of +6 at physiological pH and a hydrophobic moment optimized for bacterial membrane selectivity over mammalian membranes. Structure-activity relationship studies modifying this sequence have established which residues are essential for activity versus those that can be substituted to improve stability or reduce cytotoxicity.
